|Description||JW74 is a tankyrase-specific inhibitor. JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines. At the molecular level, JW74 induces stabilization of AXIN2, a key component of the β-catenin destruction complex, resulting in reduced levels of nuclear β-catenin. At the functional level, JW74 induces reduced cell growth in all three tested cell lines, in part due to a delay in cell cycle progression and in part due to an induction of caspase-3-mediated apoptosis. Furthermore, JW74 induces differentiation in U2OS cells, which under standard conditions are resistant to osteogenic differentiation. JW74 also enhances differentiation of OS cell lines, which do not harbor a differentiation block.|
|Appearance||white solid powder|
|Synonyms||JW74; JW-74; JW 74|
|Current Developer||Oslo University|
CDDO Imidozolide is a synthetic triterpenoid as Nrf2 signaling activator with highly active in suppressing cellular proliferation of human leukemia and breast c...
Pioglitazone significantly attenuates left ventricular (LV) cavity dilatation and dysfunction by echocardiography as well as LV end-diastolic pressure in mice w...
WY 14643 (Pirinixic Acid) is a potent peroxisome proliferator and activator of PPARα with EC50 of 1.5 μM.
Indeglitazar is a peroxisome proliferator-activated receptor (PPAR) pan-agonist. Phase II clinical trials for Type 2 diabetes mellitus was discontinued.
Arhalofenateis, also known as JNJ-39659100 and MBX102, as an uricosuric agent it is a selective, partial PPAR-γ agonist.
GSK7227 is a novel class of PPARdelta partial agonists. It shows potent partial agonism of the PPARdelta target genes CPT1a and PDK4 in skeletal muscle cells.
Rosiglitazone exhibits insulin-sensitising activity 60- to 200-fold higher than that of troglitazone, englitazone, or piogliazone in rodent models of insulin re...
CS-7017 monohydrate is a peroxisome proliferator activated receptor gamma (PPAR) agonist. It is a potential therapy for thyroid cancer and liposarcoma. It is al...
PPARγ is a ligand-activated nuclear receptor and was reported to plays a role in energy metabolism, glucose homeostasis and microglia-mediated neuroinflammation...
SR 1664 is a PPARγ (peroxisome proliferator-activated receptor γ ) inhibitor. SR 1664 can block PPARγ by cyclin-dependent kinase 5 with an IC50 value of 80 nM a...
Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity as a drug for the treatment...
Bezafibrate (marketed as Bezalip and various other brand names) is a fibrate drug used for the treatment of hyperlipidaemia. It helps to lower LDL cholesterol a...
The dihydrochloride salt form of DG-172, a piperazin drrivative, is a PPARβ/δ inverse agonist that could promote cell differentiation of dendritic induced by GM...
Inolitazone is an orally bioavailable PAPR-gamma inhibitor with potential antineoplastic activity. Inolitazone binds to and activates peroxisome proliferation-a...
Saroglitazar magnesium is a dual PPAR agonist with potent predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, res...
CC-618 has been found to be a PPARβ/δ antagonist that could be used to study the potential biological activity of Cys249 at some extent. IC50: 10 μM.
Seladelpar is a selective peroxisome proliferator-activated receptor -δ receptor agonist. Phase II clinical trials for the treatment of Hyperlipidaemia, Hyperli...
Pioglitazone HCl is a hydrochloride salt form of pioglitazone which is a cytochrome P450 (CYP)2C8 and CYP3A4 enzymes inhibitor for CYP2C8, CYP3A4 and CYP2C9 wit...
L-165041 is a cell permeable PPARδ agonist which induces adipocyte differentiation in NIH-PPARδ cells. It displays more than 100-fold selectivity for both mouse...
MCC-555, a thiazolidinedion derivative, has been found to be a PPAR agonist that was once studied as hyperglycaemic and hyperlipidaemic. The Phase II trial agai...